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discontinuation was 7 (range: 2-56) and 10 (range: 2-48), respectively. Pre-in-
fusion steroids were re-started in 3 patients after a rise in sUA, with 1 regain-
ing sUA response (patient 2) and 2 discontinuing therapy (patients 4 and 9). 
An additional patient had a loss of sUA response (patient 7) and discontinued, 
1 patient discontinued due to hospitalization (patient 6), and 1 patient chose 
to discontinue therapy (patient 8). At the time of data collection, 4 patients 
remained on therapy (patients 1-3, 5). Eight patients had at least one AE (all 
deemed unrelated to treatment), including influenza, hypertensive crisis, and 
toe amputation. No IRs occurred.
Conclusion: In this case series, 8 of 9 patients received 6 months or more (≥12 
infusion) of pegloticase. These cases suggest that pre-infusion GC discontin-
uation may be possible in some patients treated with pegloticase (particularly 
those over 70 years). Further investigation exploring this concept is warranted, 
including evaluating the optimal time and conditions to discontinue pre-infusion 
GCs with pegloticase.
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Background: Synovial fluid analysis (SFA) via compensated polarized light 
microscopy is still considered the gold standard for the identification and 
diagnosis of Calcium Pyrophosphate Deposition disease (CPPD)-related 
arthropathies[1], but very few studies have been published about its diagnos-
tic accuracy.
Objectives: The aim of this study was to evaluate the accuracy of SFA in the 
identification of calcium pyrophosphate dihydrate (CPP) crystals compared to 
microscopic analysis of joint tissues as the reference standard.
Methods: This is an ancillary study of an international, multicentre cross-sec-
tional study performed by the CPPD subgroup of the OMERACT Ultrasound 
working group[2]. Consecutive patients with knee osteoarthritis (OA) waiting 
for total knee replacement surgery were enrolled in the study from 2 partic-
ipating centres, Mexico and Romania. During surgical procedures synovial 
fluid (SF), menisci and hyaline cartilage were collected and analysed within 
48 hours after surgery under transmitted light microscopy and compensated 
polarised light microscopy for the presence/absence of CPP crystals. All 
slides were analysed by expert examiners on site, blinded to other find-
ings. A dichotomic score (absence/presence) was used for scoring both SF 
and tissues. Microscopic analysis of knee tissues was considered the gold 
standard. Sensitivity, specificity, accuracy, positive and negative predictive 
values (PPV and NPV) of SFA in the identification of CPP crystals were 
calculated.
Results: 15 patients (53% female, mean age 68yo ± 8.4) with OA of grade 3 
or 4 according to Kellgren-Lawrence scoring were enrolled. 12 patients (80%) 
were positive for CPP crystals at SFA and 14 (93%) at tissues microscopic anal-
ysis. Among 12 SFA positive patients, all were positive for CPP crystals in either 
medial or lateral meniscus, and 11 were positive in both; 10 patients were positive 
at the hyaline cartilage, and all 10 were also positive for at least one meniscus. 
Regarding the 3 SFA negative patients, only one had no crystals in the examined 
tissues, while the other 2 patients had CPP crystals in both menisci and hyaline 
cartilage. The overall diagnostic accuracy of SFA compared to histology analysis 
for CPPD was 87%, with a sensitivity of 86% and a specificity of 100%, the PPV 
was 100% and the NPV was 33% (Table 1).
Table 1. sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV) and diagnostic accuracy of synovial fluid analysis 
compared to the reference standard. CI: Confidential Interval. SF: synovial 
fluid, in parentheses: numerators and denominators for all percentages 
provided.
 Sensitivity Specificity PPV NPV Accuracy
SF analysis 86% (12/14) 100% (1/1) 100% (12/12) 33% (1/3) 87% (13/15)









Conclusion: SFA demonstrated to be an accurate test for the identification of 
CPP crystals in patients with advanced OA. However, is not always feasible and 
carries some risks for the patient. Considering the availability of validated imag-
ing techniques for the detection of CPPD, such as US, SFA could be used in 
those patients where imaging and clinical data are not definitely confirmatory of 
the disease.
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